Michael Buschle
Directeur/Bestuurslid bij VICORE PHARMA HOLDING AB
Actieve functies van Michael Buschle
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
VICORE PHARMA HOLDING AB | Directeur/Bestuurslid | 01-01-2023 | - |
HBM Partners AG
HBM Partners AG Investment ManagersFinance HBM Partners AG (HBM-P) was established in 2001 as an independent provider of investment advisory services with headquarters in Zug, Switzerland. HBM-P's field of expertise comprises global human medicine, biotechnology, medical technology and related sectors. The firm primarily advises HBM BioVentures AG and HBM BioCapital via their Cayman Islands-based, wholly-owned subsidiary, HBM Partners (Cayman) Ltd., which acts as the investment manager for the HBM funds. They rely on the services of an external consultant to analyze investment opportunities in the US. | Private Equity Investor | 01-01-2017 | - |
Loopbaan van Michael Buschle
Eerdere bekende functies van Michael Buschle
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Y-MABS THERAPEUTICS, INC. | Directeur/Bestuurslid | 01-10-2017 | 11-12-2018 |
Independent Dir/Board Member | 01-10-2017 | 11-12-2018 | |
GLENMARK PHARMACEUTICALS LIMITED | Hoofd Techniek/Wetenschap/O&O | 23-01-2012 | - |
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | Hoofd Techniek/Wetenschap/O&O | 03-12-1997 | - |
Oprichter | 03-12-1997 | - |
Statistieken
Internationaal
Oostenrijk | 2 |
India | 2 |
Zwitserland | 2 |
Operationeel
Chief Tech/Sci/R&D Officer | 2 |
Director/Board Member | 2 |
Founder | 1 |
Sectoraal
Health Technology | 5 |
Finance | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 3 |
---|---|
GLENMARK PHARMACEUTICALS LIMITED | Health Technology |
Y-MABS THERAPEUTICS, INC. | Health Technology |
VICORE PHARMA HOLDING AB | Health Technology |
Bedrijven in privébezit | 2 |
---|---|
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | Health Technology |
HBM Partners AG
HBM Partners AG Investment ManagersFinance HBM Partners AG (HBM-P) was established in 2001 as an independent provider of investment advisory services with headquarters in Zug, Switzerland. HBM-P's field of expertise comprises global human medicine, biotechnology, medical technology and related sectors. The firm primarily advises HBM BioVentures AG and HBM BioCapital via their Cayman Islands-based, wholly-owned subsidiary, HBM Partners (Cayman) Ltd., which acts as the investment manager for the HBM funds. They rely on the services of an external consultant to analyze investment opportunities in the US. | Finance |
- Beurs
- Insiders
- Michael Buschle
- Ervaring